戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 compared daunorubicin/AraC plus fractionated gemtuzumab (DAGO2) with CPX-351 (CPX) (1:2 randomisation
2 ceive an initial dose of the immunoconjugate gemtuzumab ozogamicin (6 mg/m(2) intravenously).
3          Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoco
4 Induction 2 consisted of ADE with or without gemtuzumab ozogamicin (GO anti-CD33 monoclonal antibody)
5 ated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in
6 ) and arsenic trioxide (ATO) with or without gemtuzumab ozogamicin (GO) but without traditional cytot
7                                              Gemtuzumab ozogamicin (GO) contains an anti-CD33 antibod
8                           Emerging data with gemtuzumab ozogamicin (GO) demonstrate target validity a
9  Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults w
10               We investigated treatment with gemtuzumab ozogamicin (GO) in 51 patients aged 65 years
11 ndomized phase 3 trial evaluating the use of gemtuzumab ozogamicin (GO) in an intensive consolidation
12 ated the efficacy of this regimen with added gemtuzumab ozogamicin (GO) in high-risk patients.
13                   The encouraging results of gemtuzumab ozogamicin (GO) in newly diagnosed AML, and p
14 1 provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity.
15                                              Gemtuzumab ozogamicin (GO) is a novel immunoconjugate th
16                                              Gemtuzumab ozogamicin (GO) is an immunoconjugate between
17 stic impact of NPM1mut MRD and the effect of gemtuzumab ozogamicin (GO) on NPM1mut TLs and the cumula
18 igated the impact of the CD33-targeted agent gemtuzumab ozogamicin (GO) on survival in pediatric pati
19 y Group (SWOG), which tested the addition of gemtuzumab ozogamicin (GO) to a 317 regimen in a randomi
20                                  Addition of gemtuzumab ozogamicin (GO) to induction chemotherapy imp
21 val for the majority of patients when adding gemtuzumab ozogamicin (GO) to induction chemotherapy.
22 lar events on the benefit of the addition of gemtuzumab ozogamicin (GO) to standard front-line chemot
23 ted the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and pos
24                                     In 2000, gemtuzumab ozogamicin (GO) was granted accelerated appro
25                                      Purpose Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjug
26                                              Gemtuzumab ozogamicin (GO), a monoclonal antibody used i
27  (AML) leukemic blasts and is the target for gemtuzumab ozogamicin (GO), a toxin-conjugated anti-CD33
28                                              Gemtuzumab ozogamicin (GO), an immunoconjugate of an ant
29 ction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO).
30 oid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO).
31           The antibody-targeted therapeutic, gemtuzumab ozogamicin (GO, Mylotarg), is approved for tr
32 n the role of postconsolidation therapy with gemtuzumab ozogamicin (GO; Mylotarg) in children with ac
33                                              Gemtuzumab ozogamicin (GO; Mylotarg), a novel immunoconj
34 side (ADE) (n = 465) and the augmented ADE + gemtuzumab ozogamicin (GO; n = 466) arms of AAML0531 tri
35                                        While gemtuzumab ozogamicin (GTMZ) is commonly used in the tre
36                                              Gemtuzumab ozogamicin (Mylotarg) targets leukemia cells
37 momab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.
38 oconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Mylotarg), is a clinically valida
39  Liver injury developed in 11 patients after gemtuzumab ozogamicin administration; it was manifested
40 utilization of two leukaemia-directed ADCs - gemtuzumab ozogamicin and inotuzumab ozogamicin - as wel
41 e development of therapeutic ADCs, including gemtuzumab ozogamicin and inotuzumab ozogamicin, provide
42 for which there are substantial literatures: gemtuzumab ozogamicin and inotuzumab ozogamicin; and tra
43 t Pgp plays a role in clinical resistance to gemtuzumab ozogamicin and suggest that treatment trials
44        Antibody-directed therapy by means of gemtuzumab ozogamicin as an adjunct to induction chemoth
45                                              Gemtuzumab ozogamicin can be safely added to conventiona
46 ples from relapsed AML patients eligible for gemtuzumab ozogamicin clinical trials were assayed for P
47                              The addition of gemtuzumab ozogamicin did not increase the proportion of
48 wed the course of 23 patients who were given gemtuzumab ozogamicin for AML that had relapsed after he
49 pt has been reinvigorated by the approval of gemtuzumab ozogamicin for treatment of acute myeloid leu
50  May 1, 2013, that included an assessment of gemtuzumab ozogamicin given to adults (aged 15 years and
51 atic sinusoidal liver injury developed after gemtuzumab ozogamicin infusion.
52 ilure or sepsis at a median of 40 days after gemtuzumab ozogamicin infusion.
53 hat was sustained for at least 60 days after gemtuzumab ozogamicin infusion.
54         Emerging clinical data indicate that gemtuzumab ozogamicin is efficacious not only for acute
55 eatment of acute myeloid leukemia (AML) with gemtuzumab ozogamicin may result in liver injury.
56 isease, 19; refractory disease, 10) received gemtuzumab ozogamicin ranging from 6 to 9 mg/m2 per dose
57          However, the contribution of Pgp to gemtuzumab ozogamicin resistance is poorly defined.
58           These data suggest that the use of gemtuzumab ozogamicin should be reassessed and its licen
59                     However, the addition of gemtuzumab ozogamicin significantly reduced the risk of
60 tion of sinusoidal collagen, suggesting that gemtuzumab ozogamicin targets CD33(+) cells residing in
61 atient data to assess the efficacy of adding gemtuzumab ozogamicin to induction chemotherapy in adult
62               However, survival benefit from gemtuzumab ozogamicin was not associated with MFC-MRD ch
63                                              Gemtuzumab ozogamicin was relatively well tolerated at 6
64 geting the CD33 differentiation antigen with gemtuzumab ozogamicin was the first attempt of such an a
65                                              Gemtuzumab ozogamicin was the first example of antibody-
66  and suggest that treatment trials combining gemtuzumab ozogamicin with MDR reversal agents are warra
67 concomitant azole antifungal prophylaxis and gemtuzumab ozogamicin with the first course of chemother
68 mbines CD33-targeted CAR-T cells, or the ADC Gemtuzumab Ozogamicin with the transplantation of hemato
69 both Mylotarg(TM) (antibody-drug conjugate - gemtuzumab ozogamicin) and Rapamune(R) (sirolimus nanocr
70      CD33-directed antibody-drug conjugates (gemtuzumab ozogamicin) have been shown to improve overal
71 d by azacitidine, 75 mg/m(2) for 7 days, and gemtuzumab ozogamicin, 3 mg/m(2) on day 8, in older pati
72 ated the safety and efficacy of single-agent gemtuzumab ozogamicin, a humanized anti-CD33 antibody-ta
73 r patients benefit from the incorporation of gemtuzumab ozogamicin, an anti-CD33 mAb toxin, into indu
74                                              Gemtuzumab ozogamicin, an immunoconjugate of an anti-CD3
75                                    Mylotarg (gemtuzumab ozogamicin, CMA-676; Wyeth-Ayerst Laboratorie
76 out a single dose of the monoclonal antibody gemtuzumab ozogamicin, followed by autologous stem-cell
77  effective agents, such as purine analogs or gemtuzumab ozogamicin, is still under investigation, whe
78      Such agents include the immunoconjugate gemtuzumab ozogamicin, multidrug resistance inhibitors,
79 e anthracycline, adding other agents such as gemtuzumab ozogamicin, or through 'timed sequential' the
80       Using the CD33 antibody-drug conjugate Gemtuzumab Ozogamicin, we show resistance of engrafted,
81                                     In vitro gemtuzumab ozogamicin--induced apoptosis was also evalua
82 s predicted a greater or lesser benefit from gemtuzumab ozogamicin.
83  less than 3.5 months after the last dose of gemtuzumab ozogamicin; 6 (40%) developed VOD.
84 tor); the anti-CD33 antibody-drug conjugate, gemtuzumab ozogamicin; the oral, poorly absorbable hypom
85                              We administered gemtuzumab ozogamycin ("mylotarg"; 9 mg/m(2) day 1 or 5)
86  received chemotherapy, generally 9 mg/m2 of gemtuzumab ozogamycin(GO) on day 1 of induction.
87        Other additions include reapproval of gemtuzumab ozogomycin to target CD33, glasdegib to targe
88 bodies, which contain the variable region of gemtuzumab, results in homogeneous, systemically non-tox